Developer docs
API playgroundTry for free, no card

Search company profiles

Oryzon Genomics SA

Full company profile

uuid0002lvo

Namestring
Oryzon Genomics SA
Legal namestring
ORYZON GENOMICS S.A.
Websiteurl
oryzon.com
Company typeenum
Public
Founded yearint
2000
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epigenetic therapeutics, clinical-stage biopharmaceuticals, LSD1 inhibitors, oncology drug development, CNS disorder treatments
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development
TypeLicensing Royalties
Description

Pre-revenue clinical stage biopharmaceutical company developing epigenetic therapies. Revenue expected from future drug approvals and commercialization.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Oryzon Genomics develops small-molecule epigenetic therapeutics targeting LSD1 and HDAC6 enzymes for cancer and central nervous system disorders. The pipeline is anchored by two clinical-stage covalent LSD1 inhibitors—Iadademstat (ORY-1001) in oncology indications and Vafidemstat (ORY-2001) in CNS indications—and one preclinical HDAC6 inhibitor (ORY-4001) for neurological diseases. The company has no commercialized products and currently operates as a clinical-stage developer preparing assets for out-licensing or co-development with larger pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100% overall response rate in first-line AML patients with iadademstat
+3 more records
Product overview1 text field

Oryzon Genomics SA is a clinical-stage biopharmaceutical company developing epigenetic medicines for oncology and CNS disorders. The company has two main LSD1 inhibitors in clinical development: iadademstat (ORY-1001) for hematological malignancies including acute myeloid leukemia, and vafidemstat (ORY-2001) for psychiatric and neurological disorders. Additionally, ORY-4001 is a selective HDAC6 inhibitor in preclinical development for neurological diseases.

Product and service3 records
1Iadademstat (ORY-1001)
CategoryOncology drug candidate
2Vafidemstat (ORY-2001)
CategoryCNS drug candidate
3ORY-4001
CategoryNeurology drug candidate
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Yale University
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-09
Description

Investigator-initiated Phase Ib trial evaluating iadademstat with radiotherapy and atezolizumab for extensive stage small cell lung cancer. Trial sponsored and conducted by Yale University.

2Medical College of Wisconsin
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-23
Description

Investigator-initiated Phase I trial evaluating iadademstat with azacitidine in myelodysplastic syndrome. Principal Investigator: Dr. Guru Subramanian Guru Murthy.

3National Cancer Institute (NCI)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-13
Description

CRADA agreement for clinical development of iadademstat. NCI-sponsored Phase I trial of iadademstat with venetoclax and azacitidine in first-line AML. Principal Investigator: Dr. Natalie Galanina. Expected to recruit 45 patients.

4Oregon Health & Science University (OHSU) Knight Cancer Institute
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-13
Description

Investigator-initiated Phase I study of iadademstat with venetoclax and azacitidine in first-line AML. Principal Investigator: Dr. Curtis Lachowiez.

5Fox Chase Cancer Center
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-24
Description

Collaborative Phase II trial of iadademstat with paclitaxel in platinum-refractory/relapsed small cell lung cancer and high-grade extrapulmonary neuroendocrine tumors.

6European partners (BRAVE Project)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-12-16
Description

EU-funded BRAVE Project evaluating iadademstat role in cancer immunotherapy. Collaboration with Danish and European partners to assess efficacy in combination with checkpoint inhibitors and vaccines in solid tumors over two years.

7Memorial Sloan Kettering Cancer Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-16
Description

NCI-sponsored Phase I/II trial of iadademstat with immune checkpoint inhibitors in first-line metastatic small cell lung cancer. Principal Investigator: Dr. Charles Rudin.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Epizyme
TypeDirect peer
Description

Clinical-stage epigenetic oncology company developing EZH2 inhibitors (TAZVERIK) and other chromatin-targeting therapies. Comparable to Oryzon as a small-cap, clinical-stage epigenetic drug developer; acquired by Ipsen in 2022.

2Sage Therapeutics
TypeDirect peer
Description

Clinical-stage CNS biopharmaceutical company developing novel therapeutics for depression and other brain disorders. Comparable to Oryzon's vafidemstat as a small-cap, CNS-focused clinical-stage biotech with a single platform approach to CNS indications.

3Constellation Pharmaceuticals
TypeEmerging player
Description

Clinical-stage developer of epigenetic drugs for cancer and inflammatory diseases, including EZH2 and other chromatin-modulating targets. Closely analogous business model to Oryzon's clinical-stage epigenetic approach; acquired by MorphoSys in 2021.

4Acadia Pharmaceuticals
TypeBroad incumbent
Description

Established CNS-focused biopharmaceutical company commercializing therapies for Parkinson's disease psychosis, Rett syndrome, and other CNS disorders. Broader incumbent comparable to Oryzon's CNS franchise given overlap in neuropsychiatric indications and CNS commercial know-how.

5Karuna Therapeutics
TypeDirect peer
Description

CNS-focused clinical-stage biotech with late-stage assets in schizophrenia and other psychiatric indications. Most directly comparable to Oryzon's vafidemstat CNS franchise, particularly for negative symptoms and BPD-adjacent indications; acquired by Bristol-Myers Squibb in 2024.

6Imago BioSciences
TypeDirect peer
Description

Clinical-stage developer of LSD1 inhibitors for myeloid malignancies and other diseases. Most direct mechanistic peer to Oryzon's iadademstat; acquired by Merck in 2023 for approximately $1.35B, validating the strategic value of selective LSD1 programs in this space.

7BioXcel Therapeutics
TypeEmerging player
Description

Clinical-stage biopharmaceutical company applying AI to identify and develop transformative medicines in immuno-oncology and neuroscience. Comparable to Oryzon's vafidemstat given its CNS focus and small-cap clinical-stage profile.

8Aprea Therapeutics
TypeEmerging player
Description

Clinical-stage oncology company developing small-molecule therapies targeting the p53 pathway in hematologic malignancies and solid tumors. Comparable to Oryzon's iadademstat given shared focus on AML and small-molecule epigenetic/mechanism-targeted oncology drug development.

9Galapagos NV
TypeRegional player
Description

European clinical-stage biopharmaceutical company developing small-molecule therapies, with historical focus on inflammation and oncology. Comparable to Oryzon as a publicly listed European clinical-stage biotech of similar size and capital structure profile.

10GlycoMimetics
TypeEmerging player
Description

Clinical-stage company developing glycobiology-based therapies for AML and other hematologic malignancies. Comparable to Oryzon's iadademstat as a small-cap AML-focused clinical-stage biotech; acquired by Innovent Biologics in 2023.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds29 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oryzon Genomics SA

Clinical-Stage Biopharmaceuticalsoryzon.com

Oryzon Genomics SA firmographics

Firmographics
Name
Oryzon Genomics SA
Legal name
ORYZON GENOMICS S.A.
Website
https://oryzon.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Where Oryzon Genomics SA is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices3 records

Markets served

Oryzon Genomics SA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pharmaceutical Development: Pre-revenue clinical stage biopharmaceutical company developing epigenetic therapies. Revenue expected from future drug approvals and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Oryzon Genomics SA product offering

Product offering

Core offering

Oryzon Genomics develops small-molecule epigenetic therapeutics targeting LSD1 and HDAC6 enzymes for cancer and central nervous system disorders. The pipeline is anchored by two clinical-stage covalent LSD1 inhibitors—Iadademstat (ORY-1001) in oncology indications and Vafidemstat (ORY-2001) in CNS indications—and one preclinical HDAC6 inhibitor (ORY-4001) for neurological diseases. The company has no commercialized products and currently operates as a clinical-stage developer preparing assets for out-licensing or co-development with larger pharmaceutical partners.

Product overview

Oryzon Genomics SA is a clinical-stage biopharmaceutical company developing epigenetic medicines for oncology and CNS disorders. The company has two main LSD1 inhibitors in clinical development: iadademstat (ORY-1001) for hematological malignancies including acute myeloid leukemia, and vafidemstat (ORY-2001) for psychiatric and neurological disorders. Additionally, ORY-4001 is a selective HDAC6 inhibitor in preclinical development for neurological diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Iadademstat (ORY-1001)
  • Vafidemstat (ORY-2001)
  • ORY-4001

Quantifiable outcome

  • 100% overall response rate in first-line AML patients with iadademstat
  • +3 more outcomes

Companies that use Oryzon Genomics SA

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Oryzon Genomics SA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Oryzon Genomics SA partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor and core.

  • Yale UniversityminorStrategic or Co-development Partner · 9 February 2026Investigator-initiated Phase Ib trial evaluating iadademstat with radiotherapy and atezolizumab for extensive stage small cell lung cancer. Trial sponsored and conducted by Yale University.
  • Medical College of WisconsinminorStrategic or Co-development Partner · 23 January 2025Investigator-initiated Phase I trial evaluating iadademstat with azacitidine in myelodysplastic syndrome. Principal Investigator: Dr. Guru Subramanian Guru Murthy.
  • National Cancer Institute (NCI)coreStrategic or Co-development Partner · 13 January 2025CRADA agreement for clinical development of iadademstat. NCI-sponsored Phase I trial of iadademstat with venetoclax and azacitidine in first-line AML. Principal Investigator: Dr. Natalie Galanina. Expected to recruit 45 patients.
  • Oregon Health & Science University (OHSU) Knight Cancer InstitutecoreStrategic or Co-development Partner · 13 January 2025Investigator-initiated Phase I study of iadademstat with venetoclax and azacitidine in first-line AML. Principal Investigator: Dr. Curtis Lachowiez.
  • Fox Chase Cancer CenterminorStrategic or Co-development Partner · 24 October 2024Collaborative Phase II trial of iadademstat with paclitaxel in platinum-refractory/relapsed small cell lung cancer and high-grade extrapulmonary neuroendocrine tumors.
  • European partners (BRAVE Project)minorStrategic or Co-development Partner · 16 December 2022EU-funded BRAVE Project evaluating iadademstat role in cancer immunotherapy. Collaboration with Danish and European partners to assess efficacy in combination with checkpoint inhibitors and vaccines in solid tumors over two years.
  • Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development Partner · 16 December 2022NCI-sponsored Phase I/II trial of iadademstat with immune checkpoint inhibitors in first-line metastatic small cell lung cancer. Principal Investigator: Dr. Charles Rudin.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Oryzon Genomics SA competitors and assessment

Company assessment

Direct peers

  • Epizyme: Clinical-stage epigenetic oncology company developing EZH2 inhibitors (TAZVERIK) and other chromatin-targeting therapies. Comparable to Oryzon as a small-cap, clinical-stage epigenetic drug developer; acquired by Ipsen in 2022.
  • Sage Therapeutics: Clinical-stage CNS biopharmaceutical company developing novel therapeutics for depression and other brain disorders. Comparable to Oryzon's vafidemstat as a small-cap, CNS-focused clinical-stage biotech with a single platform approach to CNS indications.
  • Karuna Therapeutics: CNS-focused clinical-stage biotech with late-stage assets in schizophrenia and other psychiatric indications. Most directly comparable to Oryzon's vafidemstat CNS franchise, particularly for negative symptoms and BPD-adjacent indications; acquired by Bristol-Myers Squibb in 2024.
  • Imago BioSciences: Clinical-stage developer of LSD1 inhibitors for myeloid malignancies and other diseases. Most direct mechanistic peer to Oryzon's iadademstat; acquired by Merck in 2023 for approximately $1.35B, validating the strategic value of selective LSD1 programs in this space.

Emerging players

  • Constellation Pharmaceuticals: Clinical-stage developer of epigenetic drugs for cancer and inflammatory diseases, including EZH2 and other chromatin-modulating targets. Closely analogous business model to Oryzon's clinical-stage epigenetic approach; acquired by MorphoSys in 2021.
  • BioXcel Therapeutics: Clinical-stage biopharmaceutical company applying AI to identify and develop transformative medicines in immuno-oncology and neuroscience. Comparable to Oryzon's vafidemstat given its CNS focus and small-cap clinical-stage profile.
  • Aprea Therapeutics: Clinical-stage oncology company developing small-molecule therapies targeting the p53 pathway in hematologic malignancies and solid tumors. Comparable to Oryzon's iadademstat given shared focus on AML and small-molecule epigenetic/mechanism-targeted oncology drug development.
  • GlycoMimetics: Clinical-stage company developing glycobiology-based therapies for AML and other hematologic malignancies. Comparable to Oryzon's iadademstat as a small-cap AML-focused clinical-stage biotech; acquired by Innovent Biologics in 2023.

Broad incumbents

  • Acadia Pharmaceuticals: Established CNS-focused biopharmaceutical company commercializing therapies for Parkinson's disease psychosis, Rett syndrome, and other CNS disorders. Broader incumbent comparable to Oryzon's CNS franchise given overlap in neuropsychiatric indications and CNS commercial know-how.

Regional players

  • Galapagos NV: European clinical-stage biopharmaceutical company developing small-molecule therapies, with historical focus on inflammation and oncology. Comparable to Oryzon as a publicly listed European clinical-stage biotech of similar size and capital structure profile.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Oryzon Genomics SA social profiles

Digital presence

Oryzon Genomics SA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oryzon Genomics SA leadership team

Management profile

Number of profiles

Profiles15 records

Oryzon Genomics SA funding detail

Funding detail

Funding overview

Funding rounds29 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oryzon Genomics SA M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oryzon Genomics SA

What does Oryzon Genomics SA do?

Oryzon Genomics develops small-molecule epigenetic therapeutics targeting LSD1 and HDAC6 enzymes for cancer and central nervous system disorders. The pipeline is anchored by two clinical-stage covalent LSD1 inhibitors—Iadademstat (ORY-1001) in oncology indications and Vafidemstat (ORY-2001) in CNS indications—and one preclinical HDAC6 inhibitor (ORY-4001) for neurological diseases. The company has no commercialized products and currently operates as a clinical-stage developer preparing assets for out-licensing or co-development with larger pharmaceutical partners.

Is Oryzon Genomics SA a public or private company?

Oryzon Genomics SA is a public company. It is classified as public and is currently operating.

When was Oryzon Genomics SA founded?

Oryzon Genomics SA was founded in 2000. It employs 11 to 50 people.

Where is Oryzon Genomics SA based?

Oryzon Genomics SA is headquartered in Barcelona, Spain, in the Europe region.

How does Oryzon Genomics SA make money?

One revenue line is on record: pharmaceutical Development.

Who are Oryzon Genomics SA's main competitors?

Direct peers on record are Epizyme, Sage Therapeutics, Karuna Therapeutics and Imago BioSciences. Emerging players are Constellation Pharmaceuticals, BioXcel Therapeutics, Aprea Therapeutics and GlycoMimetics. Acadia Pharmaceuticals is listed as a broad incumbent. Galapagos NV is listed as a regional player.

Does Oryzon Genomics SA have an API?

No public API is recorded for Oryzon Genomics SA.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comOryzon Genomics at Global Markets Forum 2026: AML drug shows promiseOryzon Genomics presented its lead AML drug iadademstat at Global Markets Forum 2026, citing 95% overall response and 74% pure complete remission in the ALICE-2 trial. The company plans a Phase III study targeting intermediate-risk and TP53-mutated patients, with peak U.S. sales potentially exceeding $1 billion.EXPANSIONTres pequeños valores españoles con un potencial superior al 100%Three Spanish stocks—Oryzon, Global Dominion, and Audax—have analyst price targets implying over 100% upside, with discounts of 109% to 178%. Oryzon's biotech drug iadademstat for leukemia is the key catalyst, while Global Dominion and Audax face weaker results and debt concerns. The investments are long-term and high-risk.Clinical Trials ArenaEMA approves Oryzon’s application for Phase II HOPE-2 studyThe EMA approved Oryzon Genomics' clinical trial application to begin the Phase II HOPE-2 study of vafidemstat in 12 adult patients with Phelan-McDermid syndrome in Spain. The single-arm trial will assess safety and tolerability over 12 weeks, with secondary endpoints on aggression and irritability. The study is part of the VANDAM project under NextGenerationEU funding.YahooEMA approves Oryzon’s application for Phase II HOPE-2 studyThe EMA approved Oryzon Genomics' clinical trial application to begin the Phase II HOPE-2 study of vafidemstat in 12 adult patients with Phelan-McDermid syndrome in Spain. The single-arm trial will assess safety and tolerability over 12 weeks, with possible extension to 24 weeks, and secondary endpoints on aggression and irritability.BioSpaceORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)Oryzon Genomics received EMA approval to initiate the HOPE-2 Phase II study of vafidemstat for Phelan-McDermid Syndrome, a genetic disorder associated with autism. The single-center, single-arm study will enroll 12 adult patients to evaluate safety and tolerability, with secondary objectives on aggression and overall disease efficacy. The study is funded through Oryzon's VANDAM project under Med4Cure.GlobeNewswireORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026Oryzon Genomics reported positive clinical data from its iadademstat trials at the EHA 2026 Congress, showing a 100% overall response rate (ORR), 89% composite complete remission (CRc), and 78% complete response (CR) in first-line acute myeloid leukemia patients treated with the iadademstat-azacitidine-venetoclax triplet combination. The company also raised €12 million through a capital increase and entered into a financing agreement with COFIDES, which committed to invest €25 million in future capital increases to support Oryzon's mental health programs. Oryzon reported a cash position of $16.7 million as of June 30, 2026, with net losses of $3.6 million for the first half of 2026, and continues advancing its pipeline including vafidemstat in borderline personality disorder and Phase II trials in essential thrombocythemia and sickle cell disease.European BiotechnologyOryzon raises €12m to push AML and CNS pipelineOryzon Genomics raised €12m in a capital increase and signed a COFIDES agreement that could add €25m in future share subscriptions. The funds will advance its LSD1 inhibitors iadademstat and vafidemstat, with vafidemstat's Phase III trial in borderline personality disorder pending FDA feedback. The company also reported encouraging AML data for iadademstat.Empresas de Capital Riesgo en EspaORYZON raises €12 million and signs a financing agreement with COFIDES to strengthen its balance sheet and accelerate its clinical programsOryzon Genomics raised €12 million via a capital increase at €2.70 per share, a 14.15% discount to VWAP. It signed a COFIDES agreement committing €25 million for future shares, with at least 40% of proceeds for mental health programs.Investing.comOryzon raises €12 million through share placement By Investing.comOryzon Genomics completed a €12 million capital increase by issuing 4,444,445 new shares at €2.70 per share, representing a 14.15% discount to the five-day volume-weighted average price. The company also entered a share subscription agreement with the Social Impact Fund, managed by COFIDES, committing up to €25 million for future capital increases within six months, with at least 40% of proceeds designated for mental health medicine development including borderline personality disorder and other psychiatric conditions.GlobeNewswireORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical ProgramsOryzon Genomics completed a €12 million gross capital increase by issuing 4,444,445 new ordinary shares at €2.70 per share, representing a 14.15% discount to the five-day VWAP. The company also signed a share subscription agreement with COFIDES' Social Impact Fund, which has committed up to €25 million in future capital increases to support Oryzon's mental health programs in CNS, oncology, and hematology. The proceeds will advance clinical development of iadademstat for acute myeloid leukemia and vafidemstat for CNS disorders.